CYBN:NYE-Cybin Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 9.99

Change

0.00 (0.00)%

Market Cap

USD 0.21B

Volume

0.05M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-03 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
BHVN Biohaven Pharmaceutical Holdin..

N/A

USD 5.14B
RCUS Arcus Biosciences Inc

N/A

USD 1.58B
NUVB Nuvation Bio Inc

N/A

USD 0.74B
DNA Ginkgo Bioworks Holdings

N/A

USD 0.50B
ANRO Alto Neuroscience, Inc.

N/A

USD 0.37B
ADCT ADC Therapeutics SA

N/A

USD 0.29B
ANVS Annovis Bio Inc

N/A

USD 0.12B
ARMP Armata Pharmaceuticals Inc

N/A

USD 0.09B
PLX Protalix Biotherapeutics Inc

N/A

USD 0.08B
OSTX OS Therapies Incorporated

N/A

USD 0.07B

ETFs Containing CYBN

PSY 0.00 % 0.76 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2,336.59% 88% B+ 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 2,336.59% 88% B+ 99% N/A
Trailing 12 Months  
Capital Gain 1,577.58% 91% A- 98% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 1,577.58% 91% A- 98% N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 20.24% 76% C+ 82% B
Dividend Return 20.24% 76% C+ 80% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 275.31% 15% F 4% F
Risk Adjusted Return 7.35% 52% F 27% F
Market Capitalization 0.21B 78% C+ 37% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector